The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Idiopathic Multicentric Castleman Disease

An interleukin-6-driven systemic inflammatory lymphoproliferative disorder of unknown cause

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Idiopathic Multicentric Castleman Disease?

Idiopathic multicentric Castleman disease occurs in patients without HIV or human herpesvirus 8 infection and is driven by excess interleukin-6 signaling and other dysregulated inflammatory mediators. Subtypes include TAFRO syndrome with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly.

Diagnosis requires lymph node biopsy showing characteristic Castleman histology together with systemic features and exclusion of malignancy and infection. Castleman Disease Collaborative Network criteria and the iMCD international consensus guide classification.

First-line therapy is the anti-interleukin-6 antibody siltuximab or, where unavailable, tocilizumab. Severe and TAFRO subtype disease may require corticosteroids, rituximab, and chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone, or targeted regimens such as bortezomib-based therapy.

Symptoms

Persistent fever, sweats, and weight loss
Generalized lymphadenopathy and organomegaly
Anemia and hypoalbuminemia
Polyclonal hypergammaglobulinemia
Severe edema and serous effusions in TAFRO subtype

Risk Factors

Idiopathic etiology without HIV or HHV-8
TAFRO subtype with rapid clinical deterioration
Active interleukin-6 dominant inflammatory phenotype
Renal dysfunction or thrombocytopenia at diagnosis
Histology consistent with multicentric Castleman disease

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • When fever and lymphadenopathy persist
  • When severe edema, ascites, or thrombocytopenia develop
  • When biopsy confirms Castleman histology
  • When organ dysfunction worsens despite supportive care
  • When tertiary referral is needed for therapy

Treatment Methods

01
Siltuximab or tocilizumab as first-line therapy
02
Adjunctive corticosteroids for severe inflammation
03
Rituximab for refractory disease
04
Chemotherapy with cyclophosphamide-based regimens
05
Bortezomib-based therapy in selected cases
06
Supportive care for organ dysfunction
07
Multidisciplinary review with hematology and rheumatology

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.